白癜风复发了到凯里哪治贵阳看白癜风医院到那儿正规,六盘水白癜风哪里治好,遵义白癜风能完全治愈吗,贵阳白癜风医院去哪儿好点,贵阳白癜风哪家医院治疗更正规,贵阳看白癜风到哪里医院专业,都匀有哪些治白癜风的医院

SAN DIEGO (KGTV) — Horton Plaza's sale to real-estate firm Stockdale Capital Partners hopes to revitalize the plaza back to its former glory.10News reported the downtown shopping center was in escrow back in June. Now, plans for the site's future are being released, including a hub for mixed-use offices, retail, and restaurants, according to the firm's plans. It will also get a new name: The Campus at Horton.Stockdale plans to use the center to cater to the tech industry and entice technology companies to the area.RELATED: Grocery chain suing Horton Plaza over millions in sales losses"The Campus at Horton will be a thriving innovation hub, comprised of creative office space, captivating entertainment options, urban lifestyle retail choices and contemporary food and beverage experiences, catering to leading technology and biotechnology employers, locally and nationally," Steven Yari, Managing Director of Stockdale Capital, said.The project is expected to create 3,000 - 4,000 jobs and generate more than .8 billion in annual economic activity."We're ripe in downtown for an office explosion," said Gary London, senior principal of London Moeder Advisors, a commercial real estate analytics firm. "There's been a big movement in corporate American to marry the places where people work with the places where people live."A rendering of The Campus shows the project's bold re-imagining of Horton Plaza to create an office and retail campus, green space, and transform walkways into one boardwalk through the site.RELATED: Jessop's?Jewelry closing after 125 years in San DiegoThe firm added there will be an opportunity for additional construction to add 1.5 million square feet to the site."Our hope is that this project will serve as a catalyst for bringing high-tech tenants and thousands of jobs to downtown and spur other developments that will do the same," Ashley Gosal, Inhouse counsel for Bosa Development, said.Construction on the project is expected to begin in early 2019, while the project is slated for completion in fall 2020.A series of community workshops will be held with Stockdale, the San Diego Chamber of Commerce, and Regional Economic Development Corporation to discuss the plan and gather community feedback. 2268

SAN DIEGO (KGTV) — Drone footage recently captured a rare sighting of a blue whale off San Diego's coastline, as it swims right up to a small boat.Domenic Biagini, owner of Gone Whale Watching, says he's already starting to see blue whale sightings off San Diego's coastline this season. In one video he captured, a whale swims up to his boat to investigate before disappearing below the water's surface."This year is looking like much more of a normal year," Biagini said. "I think this is really going to shape up to be a really good blue whale season."He adds that an abundance of krill and pristine conditions are leading to the sightings. Blue whales generally follow where krill are swimming in coastal waters. If there's a high level of krill, the whales will typically spend the entire summer nearby.Blue whale sightings come in spurts, Biagini says, while grey whales are more reliable, making this season even more of a treat for whale watchers.And whale watching could be a safe alternative to sight-seeing this summer, according to Biagini. He says he's currently running private charters, so groups are limited to single household unit sizes and there's enough room for people to space out."These are the largest animals that have ever lived on our planet," Biagini said. "People that get to see them, there's not many."Not a lot of information is known about the mating and breeding habits of blue whales, giving researchers even more opportunities to learn about the animals. 1498

SAN DIEGO (KGTV) — Even though Americans could start getting vaccinated in days, experts say people who get the shot will still need to wear masks and practice social distancing until scientists can answer a key question: whether immunized people can continue to spread COVID-19.The clinical trials by Pfizer and Moderna showed the two vaccines were about 95 percent effective, but what that really means is they were 95 percent effective at preventing COVID-19 symptoms.The trials did not measure whether vaccinated volunteers got infected without showing symptoms.That means “it is possible and conceivable” that immunized individuals could still be silent spreaders, said Dr. Christian Ramers of Family Health Centers of San Diego. “You’re not going to get sick, but you still get an asymptomatic case, pass it on to your grandmother and kill her.”Both the Pfizer and Moderna vaccines are injected into the arm muscle to stimulate production of antibodies. From there, the antibodies can quickly get to the lungs to fend off severe infection. But experts say the antibodies may have less access to the nose and throat, the primary entry points for the virus.Some studies have suggested that people without symptoms can still have high enough levels of coronavirus in their nose to infect other people.“The vaccine is doing something to prevent disease. We don't really know yet if it prevents transmission,” said Dr. Ramers. “So we have to fall back on all those fundamental things like distancing, masking and washing hands.”Still, experts say there are encouraging clues that vaccinated people may be less contagious. A study in October found antibody levels in the blood were similar to levels in saliva.AstraZeneca had volunteers in its trial test themselves for signs of infection and reported there were fewer asymptomatic cases. However, the company has not yet provided details and its vaccine relies on different technology than Pfizer and Moderna’s mRNA candidates.Until we know more, doctors say vaccinated people will have to keep wearing masks -- potentially until there we achieve herd immunity.“There is modeling to suggest that it will be summer until we reach the point where there are enough people vaccinated that this curve of new cases really starts to go down,” Ramers said.There’s a chance we could get good news before then. Both Pfizer and Moderna say they’ll start testing their volunteers’ blood to reveal if they got infected after vaccination.Pfizer plans to examine a subset of its volunteers. Moderna said it will analyze blood from everyone in the trial.Moderna said it will take several weeks to produce results. 2656

SAN DIEGO (KGTV) -- Drove footage captured off the coast of San Diego shows orcas happily making their way through crystal clear water. The footage was captured by Domenic Biagini Photography roughly 20 miles off the coast.Biagini told 10News that the water was perfectly calm and the skies clear, allowing for some incredible footage to be captured.Watch the full video in the player below: 409

SAN DIEGO (KGTV) — Governor Gavin Newsom’s vaccine safety task force will have to work quickly once the FDA announces a decision on Pfizer’s COVID-19 vaccine candidate.The 11-member panel, officially called the Scientific Safety Review Workgroup, has been tasked with reviewing the safety and efficacy of vaccine trials and rendering a recommendation on their use in California.The workgroup has a difficult mission: review the data thoroughly enough to offer a recommendation independent from the FDA, but do it fast enough to avoid delaying distribution of the vaccine.Pfizer’s emergency use authorization application spans thousands of pages.The workgroup has already reviewed Pfizer’s early-stage clinical trial data from phases 1 and 2 and found no cause for concern, Governor Gavin Newsom said. They’re still waiting to get their hands on the all-important Phase 3 data, which included thousands of participants.Panel member Dr. Rodney Hood, the president of the Multicultural Health Foundation, acknowledged the task force will have to complete its review of the Phase 3 data “very, very quickly.” Dr. Hood is one of two members from the San Diego region, along with Dr. Mark Sawyer of Rady Children’s Hospital.“We certainly don't want to introduce any unnecessary delay in the vaccine being available to Californians,” Dr. Sawyer said.The FDA has scheduled a meeting of its vaccine advisory committee, known by its acronym VRBPAC (pronounced verb-pack), on Dec. 10. The agency said it will make Pfizer’s Phase 3 data available at least two days before that meeting.At the end of that meeting, a group of about 20 experts on the advisory committee will vote on whether to recommend emergency authorization of the vaccine. The FDA is expected to issue a decision shortly after, although the agency does not have to abide by the advisory committee’s recommendation.“The California committee is on notice to be ready for a meeting either later in the day on the 10th or on December 11,” said Dr. Sawyer.Dr. Sawyer was recently added to VRBPAC, so he will cast a vote on whether to recommend approval of the vaccine at the national level before participating in California’s process.“It is going to take a few days for the vaccine to really start flowing,” he said. “I don't think the [California] committee is going to introduce extra delay.”The California committee has promised to issue its decision within 24 hours of the FDA’s to avoid slowing down distribution, but that means the members may have as few as three days to review the safety and efficacy data.Federal regulators will spend about three weeks reviewing the thousands of pages of data submitted as part of Pfizer’s application. VRBPAC and the California Scientific Safety Review Workgroup will render decisions based on summaries prepared by the FDA, Dr. Sawyer said.Both doctors say they have confidence in the FDA’s process and acknowledge it would be very unlikely for the California workgroup to break with the agency’s recommendation. They said the mission of their review is to add an extra layer of verification after complaints the Trump administration was exercising political pressure on the FDA.“I think the governor foresaw that it was going to be very important that the general community accept these vaccines, assuming they're approved and are safe and effective, because otherwise we're not going to get out of this pandemic,” Dr. Sawyer said.The doctors say they want to make sure that community acceptance extends across all demographics, so they’ll be looking closely at the numbers to see if various ethnic or racial groups had different responses to the vaccine.Based on research on past vaccines, a differential response is not expected, Dr. Hood said. However, COVID-19 does strike Latinos and African-Americans more severely, making vaccine acceptance among minority communities all the more critical.“I want to look at the data, get an assessment of risk-benefit and the question I ask is, would I take it? Number one. Number two, if I would take it, would I recommend it to my family?” he said.The doctors said they will also closely examine reports of side effects.Early data suggests both Pfizer and Moderna’s candidates have somewhat harder-hitting side effects than the typical flu vaccine. Dr. Sawyer compared the side effects to the recent shingles vaccine.“Your arm hurts for a day or two. You may not feel well. You may feel a little bit under the weather for the first 24 hours. You could even have a mild fever or headache,” he said, noting those symptoms typically resolve within 24 to 48 hours based on the data available so far.“That's actually a good sign. You want that to happen,” he added.Those sorts of short-term side effects are signs the body is building a strong immune response. They’re evidence the vaccines work as well as advertised, but the doctors say they won’t know for certain until they review the final numbers. 4949